Lilly shuffles executives overseeing oncology and M&A

Eli Lilly on Wednesday announced several shifts in its executive ranks, including naming Josh Bilenker, head of Loxo Oncology when it was acquired by Lilly for $8 billion earlier this year, its interim head of cancer research and early stage drug development.